Orphazyme not seeking fresh capital despite reduced cash position

After receiving a rejection from the US FDA on Friday, Orphazyme has shaved DKK 300m off its annual cash flow guidance. CEO rejects having plans to chase fresh capital.

Orphazyme CEO Christophe Bourdon | Photo: Orphazyme / PR

Although Orphazyme will be missing out on a considerable amount of money after its application to the US Food and Drug Administration (FDA) was rejected on Friday, the CEO Christophe Bourdon tells MedWatch that he does not predict that the firm will be seeking extra funds in a capital hunt.

Danske Markets Senior Analyst Thomas Bowers has previously pointed out that an FDA rejection letter might lead to the company going on the hunt for capital.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs